Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo

Cancer Letters

Volumn 328, Issue 1, 2013, Pages 95-103

  Dong, Xiaoshen ^a   Qu, Wenzhi ^a   Ma, Shuai ^a   Zhu, Zhi ^a   Zheng, Caiwei ^b   He, Anning ^a   Karlsson, Anna ^c   Xu, Ke ^a   Zheng, Xinyu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b BRANDEIS UNIVERSITY   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adenovirus; Nucleoside analog; Nucleoside kinase; Oncolysis; Suicide gene

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; CONDITIONALLY REPLICATING ADENOVIRUS; DEOXYRIBONUCLEOSIDE KINASE; GEMCITABINE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; EMBRYO; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; SUICIDE GENE THERAPY; TUMOR XENOGRAFT; WILD TYPE;

ADENOVIRIDAE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DROSOPHILA PROTEINS; FEMALE; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROMOTER REGIONS, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; DROSOPHILA MELANOGASTER;

EID: 84868481773     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.09.003     Document Type: Article

References (43)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Bernard-Marty C., Cardoso F., Piccart M.J. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004, 9:617-632.
3. Kirn D.H., Thorne S.H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 2009, 9:64-71.
4. Liu T.C., Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 2008, 15:877-884.
5. Kasuya H., Takeda S., Nomoto S., Nakao A. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther. 2005, 12:725-736.
6. Kasuya H., Nishiyama Y., Nomoto S., Goshima F., Takeda S., Watanabe I., Nomura N., Shikano T., Fujii T., Kanazumi N., Nakao A. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Ther. 2007, 14:533-542.
7. Fu X., Tao L., Li M., Fisher W.E., Zhang X. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin. Cancer Res. 2006, 12:3152-3157.
8. Zhang Q., Chen G., Peng L., Wang X., Yang Y., Liu C., Shi W., Su C., Wu H., Liu X., Wu M., Qian Q. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin. Cancer Res. 2006, 12:6523-6531.
9. Yu W., Fang H. Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 2007, 7:141-148.
10. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 2006, 98:298-300.
11. Wodarz D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res. 2001, 61:3501-3507.
12. Vorburger S.A., Hunt K.K. Adenoviral gene therapy. Oncologist 2002, 7:46-59.
13. Huang T.G., Savontaus M.J., Shinozaki K., Sauter B.V., Woo S.L. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther. 2003, 10:1241-1247.
14. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
15. Safran M., Kaelin W.G. HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Invest. 2003, 111:779-783.
16. Munch-Petersen B., Piskur J., Sondergaard L. Four deoxynucleoside kinase activities from Drosophila melanogaster are contained within a single monomeric enzyme, a new multifunctional deoxynucleoside kinase. J. Biol. Chem. 1998, 273:3926-3931.
17. Zheng X., Johansson M., Karlsson A. Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. J. Biol. Chem. 2000, 275:39125-39129.
18. Arner E.S., Spasokoukotskaja T., Eriksson S. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem. Biophys. Res. Commun. 1992, 188:712-718.
19. Zhou H., O'Neal W., Morral N., Beaudet A.L. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J. Virol. 1996, 70:7030-7038.
20. Thomas M.B., Abbruzzese J.L. Opportunities for targeted therapies in hepatocellular carcinoma. J. Clin. Oncol. 2005, 23:8093-8108.
21. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373-376.
22. Kurihara T., Brough D.E., Kovesdi I., Kufe D.W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 2000, 106:763-771.
23. Li Y., Chen Y., Dilley J., Arroyo T., Ko D., Working P., Yu D.C. Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Mol. Cancer Ther. 2003, 2:1003-1009.
24. Rodriguez R., Schuur E.R., Lim H.Y., Henderson G.A., Simons J.W., Henderson D.R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997, 57:2559-2563.
25. Takahashi M., Sato T., Sagawa T., Lu Y., Sato Y., Iyama S., Yamada Y., Fukaura J., Takahashi S., Miyanishi K., Yamashita T., Sasaki K., Kogawa K., Hamada H., Kato J., Niitsu Y. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol. Ther. 2002, 5:627-634.
26. Qian Q., Sham J., Che X., Xu J., Xue H., Cui Z., Zhu B., Wu M. Gene-viral vectors: a promising way to target tumor cells and express anticancer genes simultaneously. Chin. Med. J. (Engl) 2002, 115:1213-1217.
27. Zhang Q., Nie M., Sham J., Su C., Xue H., Chua D., Wang W., Cui Z., Liu Y., Liu C., Jiang M., Fang G., Liu X., Wu M., Qian Q. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res. 2004, 64:5390-5397.
28. Su C., Peng L., Sham J., Wang X., Zhang Q., Chua D., Liu C., Cui Z., Xue H., Wu H., Yang Q., Zhang B., Liu X., Wu M., Qian Q. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol. Ther. 2006, 13:918-927.
29. Ahn M., Lee S.J., Li X., Jimenez J.A., Zhang Y.P., Bae K.H., Mohammadi Y., Kao C., Gardner T.A. Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter. Cancer Gene Ther. 2009, 16:73-82.
30. Chiocca E.A. Oncolytic viruses. Nat. Rev. Cancer 2002, 2:938-950.
31. Everts B., van der Poel H.G. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2005, 12:141-161.
32. Chu R.L., Post D.E., Khuri F.R., Van Meir E.G. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res. 2004, 10:5299-5312.
33. Bristol J.A., Zhu M., Ji H., Mina M., Xie Y., Clarke L., Forry-Schaudies S., Ennist D.L. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol. Ther. 2003, 7:755-764.
34. Pei Z., Chu L., Zou W., Zhang Z., Qiu S., Qi R., Gu J., Qian C., Liu X. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004, 39:1371-1381.
35. Liu X.Y., Qiu S.B., Zou W.G., Pei Z.F., Gu J.F., Luo C.X., Ruan H.M., Chen Y., Qi Y.P., Qian C. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol. Ther. 2005, 11:531-541.
36. Li X., Liu Y.H., Zhang Y.P., Zhang S., Pu X., Gardner T.A., Jeng M.H., Kao C. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin. Cancer Res. 2007, 13:5463-5473.
37. Kojima Y., Honda K., Hamada H., Kobayashi N. Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models. J. Surg. Res. 2009, 157:e63-70.
38. Johansson M., van Rompay A.R., Degreve B., Balzarini J., Karlsson A. Cloning and characterization of the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster. J. Biol. Chem. 1999, 274:23814-23819.
39. Ma S., Zhao L., Zhu Z., Liu Q., Xu H., Johansson M., Karlsson A., Zheng X. The multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster as a therapeutic suicide gene of breast cancer cells. J. Gene Med. 2011, 13:305-311.
40. Zheng X., Johansson M., Karlsson A. Bystander effects of cancer cell lines transduced with the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster and synergistic enhancement by hydroxyurea. Mol. Pharmacol. 2001, 60:262-266.
41. Zhu Z., Mao L., Zhao L., Sun Z., Wang Z., Xu H., Zheng X. Synergistic therapeutic effect in gastric cancer cells produced by oncolytic adenovirus encoding Drosophila melanogaster deoxyribonucleoside kinase. Cancer Biol. Ther. 2011, 11:874-882.
42. Hui Y.F., Reitz J. Gemcitabine: a cytidine analogue active against solid tumors. Am. J. Health Syst. Pharm. 1997, 54:162-170. (quiz 197-168).
43. Knecht W., Mikkelsen N.E., Clausen A.R., Willer M., Eklund H., Gojkovic Z., Piskur J. Drosophila melanogaster deoxyribonucleoside kinase activates gemcitabine. Biochem. Biophys. Res. Commun. 2009, 382:430-433.